Literature DB >> 16632423

Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).

E Aranda1, A Abad, A Carrato, A Cervantes, J Tabernero, E Díaz-Rubio.   

Abstract

The choice of the most suitable chemotherapy schedule for the adjuvant treatment of colon cancer has been reviewed by the TTD group, as well as the principles of risk assessment for patients with stage II disease. In the light of data now available, oxaliplatin- based schedules (FOLFOX4 or FLOX) are recommended. Alternatives in special situations are monotherapy with capecitabine, UFT/LV, or 5- FU/LV in infusion. In patients with stage II disease, the indication of chemotherapy must be individualized and based on the patient's risk of recurrence (perforation, obstruction, peritumoral lymphovascular involvement, poorly differentiated histology, number of lymph nodes examined < or = 11, pre-surgical CEA), and comorbidities that can compromise the safety of treatment or survival of the patient.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16632423     DOI： 10.1007/s12094-006-0165-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  13 in total

1.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

Authors:  E Mamounas; S Wieand; N Wolmark; H D Bear; J N Atkins; K Song; J Jones; H Rockette
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

Authors:  Albert Abad; Alfredo Carrato; Matilde Navarro; Javier Sastre; Andrés Cervantes; Antonio Antón; Mercedes Martinez-Villacampa; Eugenio Marcuello; Bartomeo Massutí; Enrique Aranda; José Luis Manzano; José Luis Guallar; Eduardo Diaz-Rubio
Journal:  Clin Colorectal Cancer       Date:  2005-03       Impact factor: 4.481

3.  Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.

Authors: 
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

5.  A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Authors:  M Ychou; J-L Raoul; J-Y Douillard; S Gourgou-Bourgade; R Bugat; L Mineur; F Viret; Y Becouarn; O Bouché; E Gamelin; M Ducreux; T Conroy; J-F Seitz; L Bedenne; A Kramar
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

Review 6.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 7.  Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.

Authors:  Alvaro Figueredo; Manya L Charette; Jean Maroun; Melissa C Brouwers; Lisa Zuraw
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Authors:  Thierry Andre; Philippe Colin; Christophe Louvet; Erik Gamelin; Olivier Bouche; Emmanuel Achille; Nicolas Colbert; Catherine Boaziz; Pascal Piedbois; Nicole Tubiana-Mathieu; Arnaud Boutan-Laroze; Michel Flesch; Marc Buyse; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

9.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

10.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544
View more
  3 in total

1.  Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.

Authors:  Antonio Antón; Agustí Barnadas; Jesús Florián; Nuria Ribelles; María Lomas; Juan Lao; Ana González-Quintás; Mireia Margelí; Ana Belén Paules; Javier Gayo; Manuel Ramos
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Synchronous isolated adrenal metastasis from rectum adenocarcinoma.

Authors:  Teresa Bonfill; Emma Dotor; Anna Darnell; Alex Casalots; Jordi Bombardó; Eugeni Saigí; Carles Pericay
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

3.  Value of the identification of microsatellite instability in colorectal cancer.

Authors:  Antonio Barrasa Shaw; José Antonio López-Guerrero; Ana Calatrava Fons; Zaida García-Casado; Vicente Alapont Olavarrieta; Jorge Campos Máñez; Carlos Vázquez Albaladejo
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.